V M Lauta
Affiliation: University of Bari
- The lymphoid system in hepatitis C virus infection: autoimmunity, mixed cryoglobulinemia, and Overt B-cell malignancyF Dammacco
Department of Biomedical Sciences and Human Oncology, University of Bari Medical School, Italy
Semin Liver Dis 20:143-57. 2000..Current data indicate a higher prevalence of overt B-cell non-Hodgkin's lymphoma in HCV-infected patients, especially in some geographic areas...
- Pharmacological elements in clinical application of synthetic peptidesV M Lauta
University of Bari Medical School, Department of Biomedical Sciences and Human Oncology, Italy
Fundam Clin Pharmacol 14:425-42. 2000..Toxic side effects can be related to the administered dose as well as to metabolites derived from bacteria in which peptides have been synthesized...
- Efficacy of epoetin alfa in the treatment of anaemia of multiple myelomaF Dammacco
Department of Internal Medicine and Clinical Oncology, University of Bari, Bari, Italy
Br J Haematol 113:172-9. 2001..4 g/dl. Adverse events were similar between treatment groups. Epoetin alfa proved effective and well tolerated for treating anaemia in patients with multiple myeloma...
- The cryoglobulins: an overviewF Dammacco
University of Bari Medical School, Bari, Italy, University of Foggia Medical School, Foggia, Italy
Eur J Clin Invest 31:628-38. 2001..The cryoglobulinemic syndrome is probably the consequence of pathogenic noxae that act upon the immune system of a host in which regulation of the peripheral T cell response appears to be in some way altered...
- Interleukin-6 and the network of several cytokines in multiple myeloma: an overview of clinical and experimental dataV M Lauta
Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine and Clinical Oncology, University of Bari Medical School, Policlinico Piazza Giulio Cesare 11, 70124 Bari, Italy
Cytokine 16:79-86. 2001..In addition, IL-6 and sIL-6R serum levels correlate with the duration of survival, as high values at the time of diagnosis correlate with short duration of survival...
- A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implicationsVito Michele Lauta
Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine and Clinical Oncology, University of Bari Medical School, Policlinico, Bari, Italy
Cancer 97:2440-52. 2003....
- Pulmonary alveolar microlithiasis: an overview of clinical and pathological features together with possible therapiesVito Michele Lauta
Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine and Clinical Oncology, University of Bari Medical School, Policlinico, Piazza Giulio Cesare 11, Bari 70124, Italy
Respir Med 97:1081-5. 2003..The inability to identify clear etiological and pathogenetic elements makes difficult therapeutic approach which is palliative such as the use of diphosphonate, steroids and therapeutic BAL...
- Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trialAntonio Palumbo
Divisione di Ematologia dell Universita di Torino, Ospedale Molinette, Via Genova 3, 10126 Torino, Italy
Blood 104:3052-7. 2004..Intermediate-dose melphalan improves response rate, EFS, and OS in myeloma patients, specifically in those aged 65 to 70. It constitutes a more effective first-line regimen than standard treatment for elderly patients...
- Correlation between fatigue and hemoglobin level in multiple myeloma patients: results of a cross-sectional studyAntonio Palumbo
Haematologica 90:858-60. 2005..Multiple regression analysis adjusting for several covariates was used. Improved FACT-An scores in women and men were associated with hemoglobin increase up to sex-specific normal values...